Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies.

News Medical

United States

Pharmacy benefit managers steer Medicare patients to use their own pharmacies

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found those insured through Medicare Advantage received less expensive cancer drugs compared to others on Traditional Medicare.

Medical Xpress

Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs

Ad Fontes Media

Media Bias/Fact Check

Ian Birkby

Researchers have found that pharmacy benefit managers (PBMs) -- organizations that negotiate access to medicines for most patients in the United States -- steer patients to use their own pharmacies. However, these pharmacies appear less used in Medicare than in other market segments. These PBMs are part of integrated health care conglomerates that own insurance companies and pharmacies, which may create conflicts of interest.

All Sides

Science Daily

Daniel Hogan

Medicare rules may reduce prescription steering

An informal coalition of patient advocacy organizations, independent pharmacists and local business groups in Connecticut have come together to push for transparency around pharmacy benefit managers and their impact on patients and prescription drug costs.

CTNewsJunkie.com

New Coalition To Push For Prescription Drug Transparency In Connecticut

cornell.edu

Medicare Rules May Reduce Prescription Steering

A Weill Cornell Medicine study found that one-third of all Medicare Part D pharmacy spending and nearly 40% of specialty drug spending within Medicare Part D was through pharmacies owned by the four largest PBMs: CVS, UnitedHealth Group, Cigna and Humana.

medicaleconomics.com

Medicare rules may limit prescription steering by PBMs, study finds

A recent study has shed light on the stark differences in the accessibility and prescription rates of high-cost cancer drugs among patients diagnosed with colorectal cancer and non-small cell lung cancer, contrasting those enrolled in Medicare Advantage plans with their counterparts on Traditional Medicare. Research conducted by a group of scientists from the University of Colorado Anschutz Medical Campus reveals a significant trend; patients us…

Scienmag: Latest Science and Health News

New Study Analyzes Cost Disparities in Cancer Medications for Medicare

BIOENGINEER.ORG

The Medical Group Management Association made its demands in a letter to newly appointed leaders in the U.S. House and Senate sent Tuesday.

radiologybusiness.com

Practice managers demand ‘immediate action’ on physician Medicare pay cut

Study Reveals Cost Differences Between Medicare Advantage and Traditional Medicare Patients in Cancer Drugs

Pharmacy benefit managers steer Medicare patients to use their own pharmacies

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics